109.93
price up icon0.43%   0.47
pre-market  プレマーケット:  110.37   0.44   +0.40%
loading
前日終値:
$109.46
開ける:
$109.69
24時間の取引高:
1.61M
Relative Volume:
0.68
時価総額:
$217.12B
収益:
$51.72B
当期純損益:
$11.94B
株価収益率:
18.70
EPS:
5.88
ネットキャッシュフロー:
$13.81B
1週間 パフォーマンス:
+7.82%
1か月 パフォーマンス:
+0.80%
6か月 パフォーマンス:
-5.41%
1年 パフォーマンス:
+16.44%
1日の値動き範囲:
Value
$109.29
$110.53
1週間の範囲:
Value
$97.72
$110.53
52週間の値動き範囲:
Value
$92.35
$120.92

Novartis Ag Adr Stock (NVS) Company Profile

Name
名前
Novartis Ag Adr
Name
セクター
Healthcare (1159)
Name
電話
-
Name
住所
-
Name
職員
75,883
Name
Twitter
@novartis
Name
次回の収益日
2025-01-31
Name
最新のSEC提出書
Name
NVS's Discussions on Twitter

NVS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
109.93 217.12B 51.72B 11.94B 13.81B 5.88
Drug Manufacturers - General icon
LLY
Lilly Eli Co
757.18 680.08B 45.04B 10.59B 414.30M 11.71
Drug Manufacturers - General icon
JNJ
Johnson Johnson
153.62 344.63B 88.82B 14.07B 18.06B 5.79
Drug Manufacturers - General icon
ABBV
Abbvie Inc
176.80 312.76B 56.33B 4.28B 17.83B 2.40
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
64.49 286.27B 42.09B 14.65B 10.11B 3.2833

Novartis Ag Adr Stock (NVS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-13 ダウングレード UBS Buy → Neutral
2025-02-12 開始されました Morgan Stanley Underweight
2025-02-04 アップグレード Deutsche Bank Hold → Buy
2024-12-04 ダウングレード HSBC Securities Hold → Reduce
2024-09-11 ダウングレード BofA Securities Buy → Neutral
2024-09-05 ダウングレード Goldman Buy → Neutral
2024-09-03 ダウングレード Jefferies Buy → Hold
2024-07-19 ダウングレード Deutsche Bank Buy → Hold
2024-05-30 開始されました Goldman Buy
2024-02-23 開始されました BMO Capital Markets Market Perform
2024-01-23 開始されました Morgan Stanley Equal-Weight
2024-01-16 再開されました UBS Buy
2023-12-18 ダウングレード HSBC Securities Buy → Hold
2023-09-25 アップグレード Morgan Stanley Underweight → Equal-Weight
2023-07-14 開始されました HSBC Securities Buy
2023-04-26 アップグレード Deutsche Bank Hold → Buy
2023-03-27 アップグレード Deutsche Bank Sell → Hold
2023-01-26 ダウングレード Citigroup Buy → Neutral
2022-12-05 アップグレード Stifel Hold → Buy
2022-09-15 ダウングレード Credit Suisse Neutral → Underperform
2022-09-14 ダウングレード Berenberg Buy → Hold
2022-05-09 ダウングレード Wolfe Research Outperform → Peer Perform
2022-01-10 再開されました Citigroup Buy
2021-12-14 ダウングレード Redburn Buy → Neutral
2021-12-06 ダウングレード Exane BNP Paribas Outperform → Neutral
2021-12-03 ダウングレード Bryan Garnier Buy → Neutral
2021-09-20 ダウングレード Deutsche Bank Hold → Sell
2021-03-22 開始されました Bernstein Mkt Perform
2021-03-10 ダウングレード Argus Buy → Hold
2021-02-01 ダウングレード Cowen Outperform → Market Perform
2021-01-15 開始されました Deutsche Bank Buy
2020-09-29 開始されました Berenberg Buy
2020-09-10 アップグレード UBS Neutral → Buy
2020-09-01 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-06-15 アップグレード Citigroup Neutral → Buy
2020-03-10 アップグレード Morgan Stanley Underweight → Equal-Weight
2020-02-25 ダウングレード Guggenheim Buy → Neutral
2019-04-25 アップグレード Guggenheim Neutral → Buy
2019-04-25 アップグレード Liberum Hold → Buy
2019-04-10 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-01-02 ダウングレード JP Morgan Neutral → Underweight
2018-12-11 再開されました Jefferies Buy
2018-10-09 開始されました Guggenheim Neutral
2018-09-10 アップグレード BofA/Merrill Underperform → Buy
2018-05-29 ダウングレード HSBC Securities Buy → Hold
2018-05-25 アップグレード Credit Suisse Underperform → Neutral
2018-01-25 繰り返されました Leerink Partners Outperform
2017-12-06 ダウングレード BofA/Merrill Neutral → Underperform
2017-07-26 アップグレード Morgan Stanley Underweight → Overweight
2017-07-05 ダウングレード Credit Suisse Neutral → Underperform
2017-03-09 開始されました Liberum Buy
すべてを表示

Novartis Ag Adr (NVS) 最新ニュース

pulisher
Apr 11, 2025

Swiss pharmaceutical giant announces plans for $1.1B campus in San Diego - fox5sandiego.com

Apr 11, 2025
pulisher
Apr 11, 2025

Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties - Benzinga

Apr 11, 2025
pulisher
Apr 04, 2025

Pharma Stock Roundup: FDA Nod To SNY, AZN & NVS, JNJ Talc Suits Failure - Barchart.com

Apr 04, 2025
pulisher
Apr 03, 2025

FDA Grants Accelerated Approval To NVS Kidney Disease Drug - Barchart.com

Apr 03, 2025
pulisher
Apr 03, 2025

Quantum Corp’s Banking’s 100-Day Moving Average at 21.57: Will the Stock Break Through? - investchronicle.com

Apr 03, 2025
pulisher
Mar 27, 2025

Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar

Mar 27, 2025
pulisher
Mar 26, 2025

No room on the ARK? - Morningstar.com.au

Mar 26, 2025
pulisher
Mar 25, 2025

5 Large Drug Stocks To Watch As Industry Recovers - Barchart

Mar 25, 2025
pulisher
Mar 21, 2025

FDA Approves Novartis Drug For Rare Kidney Disease Treatment - Barchart

Mar 21, 2025
pulisher
Mar 19, 2025

Novartis scraps use of diverse panels for hires in US - Reuters

Mar 19, 2025
pulisher
Mar 14, 2025

Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart

Mar 14, 2025
pulisher
Mar 13, 2025

Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.

Mar 13, 2025
pulisher
Mar 12, 2025

Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.

Mar 12, 2025
pulisher
Mar 07, 2025

Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™ - Barchart

Mar 07, 2025
pulisher
Mar 07, 2025

Giovanni Caforio, M.D. - Novartis

Mar 07, 2025
pulisher
Mar 05, 2025

Novartis Near Buy Point; Earns Near-Best Overall Rating - Investor's Business Daily

Mar 05, 2025
pulisher
Mar 04, 2025

META_TITLE_QUOTE - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Novartis Earnings Surprised The Street; Still Going Strong - Investor's Business Daily

Mar 04, 2025
pulisher
Mar 03, 2025

Novartis Gets CHMP Opinion for Label Expansion of Fabhalta - Yahoo Finance

Mar 03, 2025
pulisher
Feb 26, 2025

AZN: 3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine - StockNews.com

Feb 26, 2025
pulisher
Feb 25, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Feb 25, 2025
pulisher
Feb 21, 2025

NVS: 3 Gene Therapy Stocks With Game-Changing Potential - StockNews.com

Feb 21, 2025
pulisher
Feb 18, 2025

NVS Quantitative Stock Analysis - Nasdaq

Feb 18, 2025
pulisher
Feb 16, 2025

Novartis: Strong Execution With A P/E Discount (NYSE:NVS) - Seeking Alpha

Feb 16, 2025
pulisher
Feb 13, 2025

Company’s Banking Stock: Dissecting a 2.21% Quarterly Revenue Decline Amid Growth - The InvestChronicle

Feb 13, 2025
pulisher
Feb 13, 2025

Novartis receives Health Canada approval for Fabhalta® oral treatment for adult patients with PNH - Barchart

Feb 13, 2025
pulisher
Feb 11, 2025

Novartis to buy Anthos Therapeutics in $3.1bn deal - Proactive Investors UK

Feb 11, 2025
pulisher
Feb 11, 2025

Novartis to buy Anthos Therapeutics in $3.1bn deal | NYSE:NVS - Proactive financial news

Feb 11, 2025
pulisher
Feb 09, 2025

Novartis 2017 Financial Results - Novartis

Feb 09, 2025
pulisher
Feb 07, 2025

ATI Inc [ATI] Records 200-Day SMA of $59.51 - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

Taking a look at what insiders are doing to gauge the America Movil S.A.B.DE C.V. ADR (AMX)’s direction - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

Novartis AG ADR [NVS] Officer makes an insider purchase of 6,566 shares worth 0.73 million. - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

NVS’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Feb 07, 2025
pulisher
Feb 07, 2025

Novartis AG ADR (NVS) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Feb 07, 2025
pulisher
Feb 06, 2025

Novartis AG ADR [NVS] is 12.85% higher this YTD. Is it still time to buy? - The DBT News

Feb 06, 2025
pulisher
Feb 06, 2025

Delhi High Court grants ad interim injunction to leading pharmaceutical company NOVARTIS; restrains use of NOVITAS mark - SCC Online

Feb 06, 2025
pulisher
Feb 03, 2025

HSBC Securities downgrades Novartis AG ADR (NVS) rating to a Reduce - Knox Daily

Feb 03, 2025
pulisher
Feb 03, 2025

2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond - sharewise

Feb 03, 2025
pulisher
Feb 03, 2025

Novartis's SWOT analysis: pharma giant's stock navigates generic headwinds - Investing.com

Feb 03, 2025
pulisher
Feb 01, 2025

Novartis Earnings: Results In-Line; Growth Brands to Offset Entresto Loss of Exclusivity in 2025 - Morningstar

Feb 01, 2025
pulisher
Jan 31, 2025

Novartis Financial Results – Q1 2021 - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis 2016 Financial Results - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis Financial Results – Q2 2023 - Novartis

Jan 31, 2025

Novartis Ag Adr (NVS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general MRK
$78.39
price down icon 0.99%
$295.30
price up icon 0.47%
drug_manufacturers_general NVO
$64.49
price down icon 2.38%
$105.68
price down icon 0.77%
drug_manufacturers_general PFE
$22.44
price up icon 1.45%
大文字化:     |  ボリューム (24 時間):